Literature DB >> 15163657

A long-term latent reservoir for HIV-1: discovery and clinical implications.

Janet D Siliciano1, Robert F Siliciano.   

Abstract

Despite the remarkable success of highly active antiretroviral therapy (HAART) for the treatment of HIV-1 infection, it now appears that the infection is intrinsically incurable with antiretroviral therapy alone. The major reason is that the virus can persist in a latent form in resting memory CD4 cells. These cells arise when infected CD4+ lymphoblasts carrying an integrated copy of the HIV-1 genome revert back to a resting memory state. In this resting state, CD4 cells are minimally permissive for virus gene expression, and infected memory cells can survive for many years. Following re-exposure to the relevant antigen or other activating stimuli, these cells can begin to produce virus again. The existence of a stable reservoir has altered treatment strategies in several ways. HAART is no longer given with the goal of eradication. In addition, the reservoir serves as a permanent archive for wild-type virus and for drug-resistant variants that arise during treatment. Thus, once resistance to a particular drug arises, the patient will always carry that resistance. Interruption in treatment results in the re-emergence of the original wild-type virus, which often replicates better than drug-resistant virus. Although HAART cannot eradicate the infection, current regimens do come close to stopping virus evolution. Free viruses found in the plasma at low levels in patients on HAART resemble viruses in the latent reservoir and do not contain new drug resistance mutations. Thus although HAART cannot produce eradication, lifetime control of the infection with antiretroviral drugs may be possible.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15163657     DOI: 10.1093/jac/dkh292

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  59 in total

1.  Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.

Authors:  Ann D Kwong; Robert S Kauffman; Patricia Hurter; Peter Mueller
Journal:  Nat Biotechnol       Date:  2011-11-08       Impact factor: 54.908

2.  Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues.

Authors:  Melissa J Churchill; Paul R Gorry; Daniel Cowley; Luxshimi Lal; Secondo Sonza; Damian F J Purcell; Katherine A Thompson; Dana Gabuzda; Justin C McArthur; Carlos A Pardo; Steven L Wesselingh
Journal:  J Neurovirol       Date:  2006-04       Impact factor: 2.643

3.  Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america.

Authors:  Alison G Abraham; Bryan Lau; Steven Deeks; Richard D Moore; Jinbing Zhang; Joseph Eron; Richard Harrigan; M John Gill; Mari Kitahata; Marina Klein; Sonia Napravnik; Anita Rachlis; Benigno Rodriguez; Sean Rourke; Constance Benson; Ron Bosch; Ann Collier; Kelly Gebo; James Goedert; Robert Hogg; Michael Horberg; Lisa Jacobson; Amy Justice; Greg Kirk; Jeff Martin; Rosemary McKaig; Michael Silverberg; Timothy Sterling; Jennifer Thorne; James Willig; Stephen J Gange
Journal:  Am J Epidemiol       Date:  2011-08-03       Impact factor: 4.897

4.  Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.

Authors:  Masayuki Amano; Pedro Miguel Salcedo-Gómez; Ravikiran S Yedidi; Rui Zhao; Hironori Hayashi; Kazuya Hasegawa; Tomofumi Nakamura; Cuthbert D Martyr; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

Review 5.  HIV Persistence in Gut-Associated Lymphoid Tissues: Pharmacological Challenges and Opportunities.

Authors:  Corbin G Thompson; Cynthia L Gay; Angela D M Kashuba
Journal:  AIDS Res Hum Retroviruses       Date:  2017-05-16       Impact factor: 2.205

6.  Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.

Authors:  Yasushi Tojo; Yasuhiro Koh; Masayuki Amano; Manabu Aoki; Debananda Das; Sarang Kulkarni; David D Anderson; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

7.  Administration of fludarabine-loaded autologous red blood cells in simian immunodeficiency virus-infected sooty mangabeys depletes pSTAT-1-expressing macrophages and delays the rebound of viremia after suspension of antiretroviral therapy.

Authors:  B Cervasi; M Paiardini; S Serafini; A Fraternale; M Menotta; J Engram; B Lawson; S I Staprans; G Piedimonte; C F Perno; G Silvestri; M Magnani
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

8.  A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.

Authors:  Masayuki Amano; Yasuhiro Koh; Debananda Das; Jianfeng Li; Sofiya Leschenko; Yuan-Fang Wang; Peter I Boross; Irene T Weber; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

9.  A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.

Authors:  Masayuki Amano; Pedro Miguel Salcedo-Gómez; Rui Zhao; Ravikiran S Yedidi; Debananda Das; Haydar Bulut; Nicole S Delino; Venkata Reddy Sheri; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

10.  Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.

Authors:  Libin Rong; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2009-10-16       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.